Corleen Roche is a distinguished finance executive with more than 25 years of experience in the biotechnology and healthcare sectors. She began her career at Deloitte, where she rose to Senior Manager in the audit practice, focusing on life sciences clients and gaining deep expertise in financial reporting, mergers and acquisitions, and regulatory compliance. Roche later held progressive leadership roles at Amgen and Spectrum Pharmaceuticals, serving as Vice President of Finance and Treasurer, where she spearheaded financial strategies that supported pipeline development and commercial launches, including navigating complex SEC filings and investor relations during periods of rapid growth. As Chief Financial Officer at CG Oncology Inc. from 2019 to 2023, Roche played a pivotal role in advancing the company's mission to develop innovative therapies for bladder cancer. She led the financial operations through critical Phase 2 and Phase 3 clinical trials, securing over $300 million in equity and debt financing to fuel the development of cretostimogene grenadenorepvec, the company's lead investigational candidate. Under her stewardship, CG Oncology achieved key milestones, including a successful initial public offering on Nasdaq in 2024, while implementing robust financial controls that enhanced operational efficiency and positioned the company for long-term sustainability. Roche's achievements have been recognized with awards such as the CFO Leadership Award from the Healthcare Financial Management Association, reflecting her strategic acumen in driving value in high-stakes biotech environments. Now serving in advisory capacities for emerging biotechs, she continues to mentor finance leaders and contribute to industry panels on capital markets and innovation funding.